	US 12,324,816 B2
	Compositions containing platelet contents
Allan B. Dietz, Chatfield, MN (US); Michael P. Gustafson, Rochester, MN (US); and Greg W. Butler, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Jan. 12, 2021, as Appl. No. 17/146,663.
Application 17/146,663 is a continuation of application No. 16/235,392, filed on Dec. 28, 2018, granted, now 10,925,901.
Application 16/235,392 is a continuation of application No. 14/957,914, filed on Dec. 3, 2015, granted, now 10,166,258, issued on Jan. 1, 2019.
Application 14/957,914 is a continuation of application No. 13/119,350, abandoned, previously published as PCT/US2009/057170, filed on Sep. 16, 2009.
Claims priority of provisional application 61/097,490, filed on Sep. 16, 2008.
Prior Publication US 2021/0154234 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/19 (2015.01); C12N 5/00 (2006.01); C12N 5/0775 (2010.01); C12N 5/078 (2010.01); C12N 5/09 (2010.01)

CPC A61K 35/19 (2013.01) [C12N 5/0037 (2013.01); C12N 5/0644 (2013.01); C12N 5/0662 (2013.01); C12N 5/0693 (2013.01); C12N 2500/90 (2013.01)]

13 Claims

1. A method for expanding a cell population for the treatment of a disease state, the method comprising:

culturing a first population of cells in the presence of medium comprising a platelet lysate composition,

wherein the platelet lysate composition comprises plasma, a total protein concentration of at least about 35 mg/mL, and 200 pg or more of VEGF polypeptide per ml, and

wherein the platelet lysate composition comprises protein complexes greater than 50 kDa.